ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2024
Incidence of Etiology-specific Hepatocellular Carcinoma: Diverging Trends and Significant Heterogeneity by Race and Ethnicity.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Mac-2 binding protein glycosylation isomer as a novel serum biomarker for recurrence in hepatocellular carcinoma.World journal of gastroenterology · 2026Pooled it
- Nativity as a Clinical Variable in Gastric Cancer Prevention: An Immigrant Health Perspective.Journal of immigrant and minority health · 2026Review
- Chronic Viral Hepatitis Screening Inequities Across Florida Federally Qualified Health Centers.Journal of racial and ethnic health disparities · 2026Article
- Risk Factors for Hepatocellular Carcinoma in Latino Populations in Texas: A Scoping Review.International journal of molecular sciences · 2026Article
- Hepatocellular Carcinoma in Southeast Asian Americans: Epidemiologic Trends, Screening Challenges, and Policy Implications.Healthcare (Basel, Switzerland) · 2026Review
- The global epidemiology of hepatocellular carcinoma.Hepatology communications · 2026Review
- Marriage and Cancer Risk: A Contemporary Population-Based Study Across Demographic Groups and Cancer Types.Cancer research communications · 2026Article
- Temporal trends and racial/ethnic disparities in hepatocellular carcinoma incidence in the US between 2000-2022.JHEP reports : innovation in hepatology · 2026Article
- Disparities in Diagnosis, Management, and Outcomes of Hepatocellular Carcinoma: A Review of Global and Sociodemographic Factors.Journal of gastrointestinal cancer · 2026Review
- Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening.Gastroenterology · 2026Article
- Burden of liver cancer and underlying etiologies in China from 1990 to 2021: A systematic analysis from the Global Burden of Disease Study 2021.Chinese medical journal · 2026Article
- Risk Scores for Stratifying Hepatocellular Carcinoma and Optimizing Surveillance Strategies.Cancers · 2026Review
- Efficacy and Safety of Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma: A Real-World Multicenter Observational Study.Oncology research · 2026Observational
- Plasma cell-CD8+ T cell co-enrichment distinguishes immunotherapy-responsive hepatocellular carcinoma subtypes.eGastroenterology · 2026Article
- Nationwide comprehensive genomic profiling defines the genomic landscape of hepatocellular carcinoma across etiologies.Scientific reports · 2025Article
- Global, regional, and national burden of liver cancer attributable to hepatitis B virus among middle-aged and older adults from 1990 to 2021 and projections to 2035: results of the Global Burden of Disease Study 2021.Journal of gastrointestinal oncology · 2025Article
- Enhanced diagnostic performance for subcentimeter hepatocellular carcinoma using a novel criterion integrating serum AFP levels and gadolinium-based contrast-enhanced MRI features.BMC medical imaging · 2025Article
- A comparison of hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: a bioinformatics analysis.Translational cancer research · 2025Article
- Temporal trends and patterns for early- and late-onset adult liver cancer incidence vary by race/ethnicity, subsite, and histologic type in the United States from 2000 to 2019.Cancer causes & control : CCC · 2025Article
- The Changing Pathogenesis of Liver Cancer in Hawaii over Three Decades.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsThe main causes of hepatocellular carcinoma (HCC) include chronic hepatitis C and B viral infections (HCV, HBV), nonalcoholic fatty liver disease (NAFLD), and alcohol-related disease (ALD). Etiology-specific HCC incidence rates and temporal trends on a population-basis are needed to improve HCC control and prevention.
methodsAll 14,420 HCC cases from the Florida statewide cancer registry were individually linked to data from the hospital discharge agency and the viral hepatitis department to determine the predominant etiology of each case diagnosed during 2010 to 2018. Age-adjusted incidence rates (AAIRs) were used to assess the intersection between etiology and detailed race-ethnicity. Etiology-specific temporal trends based on diagnosis year were assessed using Joinpoint regression.
resultsHCV remains the leading cause of HCC among men, but since 2017 NAFLD-HCC is the leading cause among women. HCV-HCC AAIRs are particularly high among U.S.-born minority men, including Puerto Rican (10.9 per 100,000), African American (8.0 per 100,000), and U.S.-born Mexican American men (7.6 per 100,000). NAFLD is more common among all Hispanics and Filipinos and HBV-HCC among Asian and Haitian black men. HCV-HCC surpasses HBV-HCC in Asian women. ALD-HCC is high among specific Hispanic male groups. Population-based HCV-HCC rates experienced a rapid decline since 2015 (-9.6% annually), whereas ALD-HCC (+6.0%) and NAFLD-HCC (+4.3%) are rising (P < .05).
conclusionsNew direct acting anti-viral drugs have impacted rates of HCV-HCC, offsetting important increases in both ALD- and NAFLD-HCC. Hispanics may be a group of concern because of higher rates for ALD- and NAFLD-HCC. HCC etiology varies remarkably and may warrant specific interventions by detailed race-ethnicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.